Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Greenworks
301260
5
Tuoxin Pharmaceutical Group
301089
(Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | 3.88%103.35B | 4.56%389.59B | 2.99%290.12B | 2.87%197.34B | 2.34%99.5B | 4.97%372.6B | 6.71%281.69B | 8.83%191.83B | 9.21%97.22B | 8.26%354.94B |
Operating revenue | 3.88%103.35B | 4.56%389.59B | 2.99%290.12B | 2.87%197.34B | 2.34%99.5B | 4.97%372.6B | 6.71%281.69B | 8.83%191.83B | 9.21%97.22B | 8.26%354.94B |
Other operating revenue | ---- | 16.53%43.61B | ---- | 4.32%21.69B | ---- | 5.14%37.43B | ---- | 35.96%20.79B | ---- | 12.28%35.6B |
Total operating cost | 3.10%93.1B | 5.29%368.99B | 1.44%264.06B | 0.69%178.6B | 1.10%90.3B | 4.99%350.44B | 6.58%260.31B | 9.57%177.37B | 7.77%89.31B | 7.45%333.8B |
Operating cost | 3.09%77.4B | 6.09%298.35B | 1.84%214.65B | 1.61%146.01B | 2.16%75.08B | 4.59%281.23B | 7.65%210.77B | 10.59%143.69B | 11.33%73.49B | 8.70%268.88B |
Operating tax surcharges | 12.80%412.45M | 10.70%1.71B | 9.20%1.21B | 8.69%802.9M | 4.37%365.64M | 10.39%1.54B | 6.46%1.11B | 4.98%738.68M | 7.07%350.34M | -2.11%1.4B |
Operating expense | 4.64%9.25B | 3.19%36.97B | 2.54%26.6B | 2.38%17.73B | 2.12%8.84B | 4.00%35.83B | 4.94%25.94B | 7.85%17.32B | 7.09%8.65B | 6.96%34.46B |
Administration expense | 0.12%4.69B | -2.47%23.4B | -11.23%16.33B | -17.03%11.08B | -16.97%4.69B | 4.42%24B | -4.51%18.39B | 0.80%13.36B | -27.77%5.64B | -7.26%22.98B |
Financial expense | -170.15%-124.14M | -7.28%-277.55M | 26.87%-157.19M | 89.52%-18.34M | -331.56%-45.95M | 65.40%-258.71M | 61.37%-214.95M | 31.04%-175.07M | 170.13%19.84M | -873.04%-747.63M |
-Interest expense (Financial expense) | -15.19%367.52M | -10.34%1.66B | -12.19%1.23B | -9.97%843.54M | 108.89%433.36M | 91.71%1.85B | 89.58%1.4B | 77.99%936.97M | -26.16%207.46M | -21.67%962.96M |
-Interest Income (Financial expense) | -4.57%-467.61M | 5.90%-1.98B | 7.83%-1.44B | 13.35%-869.75M | 3.28%-447.18M | -20.47%-2.11B | -25.50%-1.57B | -36.88%-1B | -41.78%-462.37M | -43.79%-1.75B |
Research and development | 6.65%1.47B | 9.08%8.83B | 26.01%5.44B | 22.97%2.99B | 19.00%1.38B | 18.47%8.1B | 8.41%4.32B | 11.29%2.43B | 73.85%1.16B | 42.65%6.84B |
Credit Impairment Loss | -22.59%-4.69B | -13.53%-6.97B | -77.09%-10.47B | -123.04%-7.23B | -11.83%-3.83B | 6.27%-6.14B | -30.25%-5.91B | 1.31%-3.24B | -131.29%-3.42B | -133.24%-6.55B |
Asset Impairment Loss | -32.56%-65.89M | -61.55%-347.29M | -81.13%-194.89M | -40.15%-145.14M | 20.05%-49.71M | 41.28%-214.97M | 62.80%-107.6M | 58.60%-103.56M | 42.14%-62.17M | 25.54%-366.13M |
Other net revenue | -42.80%-3.01B | 204.34%2.1B | -1,446.09%-4.11B | -519.90%-2.76B | -45.78%-2.11B | 193.25%689.83M | 66.72%-266.04M | 156.65%658.28M | -164.57%-1.45B | -245.07%-739.74M |
Fair value change income | 287.12%6.67M | -57.19%48.63M | -102.94%-3.2M | -107.49%-6.96M | -97.31%1.72M | 379.86%113.61M | 228.88%108.81M | 673.71%92.93M | 382.25%63.97M | 160.75%23.67M |
Invest income | -11.46%1.06B | -2.89%4.67B | -1.03%3.57B | 1.99%2.48B | 1.21%1.19B | 11.03%4.81B | 9.77%3.61B | 7.02%2.43B | 9.42%1.18B | -1.11%4.33B |
-Including: Investment income associates | 0.68%1.05B | -3.87%4.03B | -2.76%3.11B | -1.35%2.11B | -3.76%1.04B | 14.41%4.19B | 12.33%3.2B | 11.71%2.14B | 18.14%1.08B | 10.72%3.66B |
Asset deal income | 323.20%430.95M | 463.23%2.83B | 2,910.36%1.79B | 1,324.28%1.21B | 279.14%101.83M | 41.91%-778.4M | 104.06%59.52M | 107.18%84.77M | 91.68%-56.84M | 61.97%-1.34B |
Other revenue | -47.08%247.47M | -35.42%1.88B | -39.63%1.19B | -32.89%940.19M | -44.92%467.63M | -8.26%2.91B | -9.09%1.98B | 7.49%1.4B | 27.15%848.95M | 5.68%3.17B |
Operating profit | 2.18%7.24B | -0.63%22.7B | 3.94%21.95B | 5.67%15.98B | 9.75%7.09B | 11.97%22.84B | 11.46%21.12B | 14.38%15.12B | 15.30%6.46B | 15.29%20.4B |
Add:Non operating Income | 215.89%360.94M | 310.00%2.76B | 363.58%1.6B | 303.28%922.28M | 25.63%114.26M | -13.65%672.06M | -5.19%344.75M | 0.71%228.69M | -30.62%90.95M | 22.00%778.27M |
Less:Non operating expense | -6.10%32.82M | -54.88%363.46M | -25.59%130.17M | -6.14%81.46M | 13.31%34.95M | -0.83%805.58M | -8.92%174.93M | -37.27%86.79M | 59.07%30.84M | 54.32%812.31M |
Total profit | 5.62%7.57B | 10.49%25.09B | 10.01%23.42B | 10.20%16.82B | 9.95%7.17B | 11.50%22.71B | 11.35%21.29B | 14.68%15.26B | 14.10%6.52B | 14.38%20.37B |
Less:Income tax cost | 4.55%1.67B | 12.36%4.49B | 11.85%4.45B | 9.34%3.07B | 19.44%1.6B | 7.55%4B | 11.86%3.97B | 16.77%2.81B | 23.38%1.34B | 9.58%3.72B |
Net profit | 5.93%5.9B | 10.09%20.6B | 9.59%18.97B | 10.39%13.75B | 7.50%5.57B | 12.38%18.71B | 11.23%17.31B | 14.22%12.46B | 11.92%5.18B | 15.50%16.65B |
Net profit from continuing operation | 5.93%5.9B | 10.09%20.6B | 9.59%18.97B | 10.39%13.75B | 7.50%5.57B | 12.38%18.71B | 11.23%17.31B | 14.22%12.46B | 11.92%5.18B | 15.50%16.65B |
Net income from discontinuing operating | --0 | ---- | --0 | ---- | --0 | ---- | --0 | ---- | --0 | ---- |
Less:Minority Profit | 5.48%3.29B | 9.78%11.57B | 9.24%10.63B | 9.96%7.71B | 7.13%3.12B | 12.71%10.54B | 11.48%9.74B | 14.60%7.01B | 12.19%2.91B | 15.30%9.35B |
Net profit of parent company owners | 6.50%2.61B | 10.49%9.03B | 10.04%8.34B | 10.93%6.04B | 7.98%2.45B | 11.96%8.17B | 10.92%7.58B | 13.74%5.44B | 11.56%2.27B | 15.76%7.3B |
Earning per share | ||||||||||
Basic earning per share | 6.41%0.083 | 11.88%0.292 | 10.33%0.267 | 10.92%0.193 | 9.86%0.078 | 11.54%0.261 | 7.56%0.242 | 10.13%0.174 | 5.97%0.071 | 13.59%0.234 |
Diluted earning per share | 6.41%0.083 | 11.88%0.292 | 10.33%0.267 | 10.92%0.193 | 9.86%0.078 | 11.54%0.261 | 7.56%0.242 | 10.13%0.174 | 5.97%0.071 | 13.59%0.234 |
Other composite income | -140.92%-109.68M | -17.60%263.16M | -15.58%385.88M | -55.07%225.76M | 35.47%268.06M | 68.41%319.38M | 137.49%457.12M | -16.21%502.5M | 23.02%197.87M | 790.84%189.64M |
Other composite income of parent company owners | -140.22%-46.6M | -16.09%115.15M | -15.30%167.79M | -55.73%96.29M | 34.92%115.87M | 60.64%137.23M | 132.67%198.09M | -17.51%217.53M | 20.73%85.88M | 816.57%85.43M |
Other composite income of minority owners | -141.45%-63.08M | -18.74%148.02M | -15.80%218.09M | -54.57%129.47M | 35.90%152.19M | 74.79%182.15M | 141.31%259.02M | -15.19%284.97M | 24.84%111.99M | 771.09%104.21M |
Total composite income | -0.82%5.79B | 9.62%20.86B | 8.94%19.36B | 7.85%13.98B | 8.53%5.83B | 13.01%19.03B | 12.77%17.77B | 12.63%12.96B | 12.29%5.38B | 17.04%16.84B |
Total composite income of parent company owners | -0.13%2.56B | 10.05%9.15B | 9.39%8.51B | 8.37%6.14B | 8.96%2.56B | 12.53%8.31B | 12.41%7.78B | 12.11%5.66B | 11.87%2.35B | 17.34%7.38B |
Total composite income of minority owners | -1.35%3.23B | 9.29%11.72B | 8.59%10.85B | 7.44%7.84B | 8.19%3.27B | 13.39%10.72B | 13.06%9.99B | 13.05%7.3B | 12.61%3.02B | 16.81%9.46B |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
Auditor | -- | Deloitte Huayong Certified Public Accountants (Special General Partnership) | -- | -- | -- | Deloitte Huayong Certified Public Accountants (Special General Partnership) | -- | -- | -- | Deloitte Huayong Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.